Amova Asset Management Americas Inc. Has $279.47 Million Stake in Tempus AI, Inc. $TEM

Amova Asset Management Americas Inc. decreased its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 10.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,463,095 shares of the company’s stock after selling 406,846 shares during the period. Tempus AI accounts for about 2.7% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 9th largest holding. Amova Asset Management Americas Inc. owned 1.99% of Tempus AI worth $279,472,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Capital LLC boosted its position in shares of Tempus AI by 26.9% during the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after purchasing an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after buying an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI in the third quarter worth approximately $1,695,000. Vanguard Group Inc. grew its position in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares during the last quarter. Finally, Krane Funds Advisors LLC increased its holdings in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after buying an additional 19,358 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer owned 694,354 shares of the company’s stock, valued at $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 590,109 shares of company stock worth $37,056,566 over the last quarter. 26.27% of the stock is currently owned by corporate insiders.

Tempus AI Trading Down 0.2%

NASDAQ:TEM opened at $51.29 on Thursday. The company has a market capitalization of $9.13 billion, a P/E ratio of -36.38 and a beta of 5.29. The stock’s 50 day moving average price is $60.57 and its 200 day moving average price is $72.91. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32.

Analyst Ratings Changes

TEM has been the topic of a number of recent research reports. BTIG Research decreased their target price on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Canaccord Genuity Group dropped their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. cut their price target on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average target price of $78.15.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.